216 CHAPTER – 7 REFERENCES
216
CHAPTER – 7
REFERENCES
217
1. Sastry.S.V., Nyshadham.J.R. and Fix.J.A. Recent technological
advances in oral Drug delivery – a review. Pharm Sci Technol Today,
3, 2000; pp. 138–145.
2. Rathbone.M.J., Hadgraft.J. and Roberts.M.S. Modified release drug
delivery technology. Marcel Dekker, 2003; New York.
3. Lordi.N.G. Sustained release dosage forms. In: Lachman, L.,
Lieberman, The theory and practice of industrial pharmacy, 3rd edn.
Varghese Publishing House, Bombay, 1987; pp.430– 456.
4. Chiao.C.S.L. and Robinson.J.R. Sustained release drug delivery
systems. Remington: the science and practice of pharmacy, vol. II.
Mack Publishing Company, Easton, PA, pp. 1995; 1660–1675.
5. Kydonieus.A.F. Fundamental concepts of controlled release. In:
Controlled release technologies: Methods, theory, and applications.
vol. I. CRC, Florida, 1990; pp. 1–19.
6. Lordi N.G. "Sustained release dosage form" chapter 14 in "Theory and
practice of Industrial Pharmacy" , 3rd edition, Varghese Publishing
House, 1991;p. 430-431.
7. Welling.P.G., Dobrinska.M.R. Chapter 6 in "Controlled drug delivery:
Fundamentals and applications”, 2nd edition, Marcel Dekker Inc.,
Volume 29, 1978: pp.254-289.
8. Madhukat, Mansukalal.D, Milind, Dattatraya Joshi and Bharat
Pravinchandra. M. Pharmaceutical composition for controlled drug
delivery system, patent No: US 7,157,100 B2, ; 2007.
218
9. James Swarbrick, James C. Boylan. Encyclopedia of Pharmaceutical
Technology.2007; pp. 369-394.
10. Venkataraman Daar.S N, Chester.A, Kliener.L. An overview of
Controlled release systems, Handbook of Pharmaceutical Controlled
release technology, Marcel dekker Inc: 2000; p p.1-30.
11. Gilberts, Banker, Neil R. Anderson, Sustained release dosage forms;
The Theory and Practice of Industrial Pharmacy, 2001; 3rd edition .pp.
430- 456.
12. Rudnic E. and Schawartz J.B, Oral solid dosage forms, Remington’s
Pharmaceutical Sciences, Mack Publishing Company, Easton,
Pennsylvania,1965; pp. 2000.
13. Ahmad, A. B., Bennett, P. N. & Rowland, M. Influence of route of
hepatic administration on drug availability. Journal of Pharmacology
and Experimental Therapeutics 230, 1984; pp.718—725.
14. Joseph Robinson. R, Vincent H. L. Lee, Controlled drug delivery
fundamentals and applications, Marcel Dekker Inc, New York:3-
61.2002.
15. Birkett.D.J. Half-life, Pharmacokinetics made easy, Australian
prescriber,. 11: 1996; p.57-59.
16. Hogan, J.E. Hydroxypropylmethylcellulose sustained release
technology. Drug Dev Ind Pharm, 1989; pp. 975–999.
17. Velasco.M.V., Ford. J.L., Rowe.P. and Rajabi-Siahboomi, A.R.
Influence of drug: HPMC ratio, drug and Polymer particle size and
compression force on the release of diclofenac sodium from HPMC
tablets. J Control Release, 1999; 57, pp. 75–85.
219
18. Mitchell. K., Ford, J.L., Armstrong, D.J., Elliott, P.N., Hogan, J.E. and
Rostron, C. The influence of drugs on the properties of gels and
swelling characteristics of matrices Containing methylcellulose or
hydroxypropylmethylcellulose. Int J Pharm, 1993; pp.165–17.
19. Brand protection: tablet shape. http://www.colorcon.com
20. Dow excipients, Methocel products. http://www.dow.com/dow
excipients/products/methocel.htm
21. Ford.J.L., Rubinstein.M.H., Changela.A. and Hogan.J.E. The influence
of pH on the dissolution of promethazine hydrochloride from hpmc
controlled release tablets. J Pharm. Pharmacol, 1985; 37, pp.115-119.
22. Levina.M., Gothoskar.A. and Rajabi Siahboomi.A. Application of a
Modeling system in the formulation of extended release hydrophilic
matrices. Pharm Technol Eur, 2006; 18, pp.20–26.
23. Alderman.D.A. A review of cellulose ethers in hydrophilic matrices for
oral controlled- release dosage forms. Int J Pharm Tech Prod Manuf,
1984; 5, pp.1–9.
24. Shah, N., Railkar, A.S., Watnanee, P., Zeng, F.-U., Chen, A., Infeld,
M.H. and Malick, A.W. Effects of processing techniques in controlling
the release rate and mechanical strength of HPMV based matrices.
Eur J Pharm Biopharm, 1996; 42, pp. 183–187.
25. Levina.M. and Rajabi Siahboomi.A. The influence of excipients on
drug Release from hydroxypropyl methylcellulose matrices. J Pharm
Sci, 2004; 93, p. 2746–2754.
220
26. Horter.D. and Dressman.J.D. Influence of physicochemical
properties on Dissolution of drugs in the gastrointestinal tract. Adv
Drug Deliv Rev, 1997;25 ,pp. 3–14.
27. Vashi.V.I. and Meyer.M.C. Effect of pH on the in vitro dissolution and
in vivo absorption of controlled release theophylline in dogs. J Pharm
Sci, 1988;77, pp. 760–774.
28. Kohri.N., Miyata.N., Takahashi.M., Endo.H., Iseki.K., Miyazaki.K.,
Takechi.S and Nomura.A. Evaluation of pH-independent sustained
release granules of dipyridamole by using gastric-acidity controlled
rabbits and human subjects. Int J Pharm, 1992; 81, pp. 49–58.
29. Tatavarti.A.S. and Hoag.S.W. Microenvironmental pH modulation
based Release enhancement of a weakly basic drug from hydrophilic
matrices. J Pharm Sci, 2006; 95, pp.1459–1468.
30. Siepe.S., Herrmann.W., Borchert.H.H., Lueckel.B., Kramer.A., Ries.A.
and Gurny.R. Microenvironmental pH and micro viscosity inside pH-
controlled matrix tablets: an EPR imaging study. J Control Release,
2006; 112, pp. 72–78.
31. Tatavarti. A.S., Mehta. K.A., Augsburger. L.L. and Hoag. S.W.
Influence of methacrylic and acrylic acid polymers on the release
performance of weakly basic drugs from sustained release hydrophilic
matrices. J Pharm Sci, 2004; 93, pp. 2319–2331.
32. Siepe.S., Lueckel.B., Kramer.A., Ries.A. and Gurny.R. Strategies for
the design of hydrophilic matrix tablets with controlled
microenvironmental pH. Int J Pharm, 2006; 316, pp. 14–20.
221
33. Streubel.A., Siepmann.J., Dashevsky.A. and Bodmeier.R. pH-
independent release of a weakly basic drug from water-insoluble and
soluble matrix tablets. Jour. of Control Release, 2000; 67, pp. 101–
110.
34. Gabr.K. Effect of organic acids on release patterns of weakly basic
drugs from inert sustained release matrix tablets. Eur J Pharm
Biopharm, 1992; 38, pp. 199–202.
35. Varma.M.V.S., Kaushal.A.M. and Garg.S. Influence of micro-
environmental pH on the gel layer behavior and release of a weakly
basic drug from various hydrophilic matrices. Journal of Controlled
Release, 2005; 103, pp. 499–510.
36. O Connor. K.M. and Corrigan. O.I. Effect of basic organic excipients
on the dissolution of diclofenac salts. J Pharm Sci, 2002; 91, pp.
2271– 2281.
37. Rao.V.M., Engh.K. and Qiu.Y. Design of pH-independent controlled
release matrix tablets for acidic drugs. Int. Jour. Pharm, 2003; 252,
pp. 81–86.
38. Michelucci.J.J., Sherman. D.M. and DeNeale, R.J.Sustained release
etodolac. US Pat. 1990; 4, 966, 768.
39. Riis.T., Bauer Brandl.A., Wagner.T. and Kranz.H. pH-independent
drug release of an extremely poorly soluble weakly acidic drug from
multiparticulate extended release formulations. Eur J Pharm
Biopharm, 2007; 65, pp.78–84.
222
40. Ruff. M.D., Kalidindi.S.R. and Sutton, J.J.E. Pharmaceutical
composition containing bupropion hydrochloride and a stabilizer. US
Pat.1994; 5, 358,970.
41. Methocel cellulose ethers technical handbook. http: // www.dow.com
/ Published Literature /192–01062.
42. Mitchell.K., Ford.J.L., Armstrong. D.J., Elliott.P.N., Rostron. C. and
Hogan.J.E. The influence of additives on the cloud point,
disintegration and dissolution of Hpmc gels and matrix tablets. Int J
Pharm, 1990; 66, pp. 233–242.
43. SarkarN. Thermal gelation properties of methyl and hydroxypropyl
methylcellulose. J Appl Polym Sci,1979; 24, 1073–1087
44. Johnson.J.L., Holinej. J. and Williams, M.D. Influence of ionic
strength on matrix integrity and drug release from hydroxypropyl
cellulose compacts. Int Jour. Pharm,1993; 90, pp. 151–159.
45. Reynolds.T.D., Mitchelle.S.A. and Balwinski.K.M. Investigation of the
effect of tab let surface area/volume on drug release from
hydroxypropylmethylcellulose controlled release matrix tablets. Drug
Dev Ind. Pharm, 2002; 28, pp. 457–477.
46. Siepmann.J., Kranz.H., Peppas.N.A. and Bodmeier.R. Calculation of
the required size and shape of hydroxypropyl methylcellulose matrices
to achieve desired drug release profiles. Int Jour Pharm, 2000; 201,
pp.151–164.
47. Colombo.P., Conte.U., Gazzaniga.A., Maggi, L., Sangalli, M.E., Peppas,
N.A. and Manna, A.L. Drug release modulation by physical
restrictions of matrix swelling. Int Jour Pharm, 1990; 63, pp. 43–48.
223
48. Colombo.P., Catellani, P., Peppas, N.A., Maggi, L. and Conte, U.
Swellling characteristics of hydrophilic matrices for controlled
release: new dimensionless number to describe the swelling and
release behavior. Int Jour Pharm, 1992; 88, pp. 99–109.
49. Levina. M., Wan, P., Jordan, M. Rajabi-Siahboomi, A.R. The influence
of film coatings on performance of hypromellose matrices.2003
http://www.colorcon.com/pharma.
50. Vuong, H., Levina, M. and Rajabi-Siahboomi, A.R. The effect of film
coating and storage conditions on the performance of metformin HCl
extended release hypromellose matrices. 2006,
http:/www.colorocon.com.
51. Tiwari.S.B., Murthy.T.K., Pai.M.R., Mehta.P.R. and Chowdary. P.B.
Controlled release formulation of tramadol hydrochloride using
hydrophilic and hydrophobic matrix system. AAPS Pharm Sci Tech,
2003; 4.pp.31.
52. Dias, V.D., Gothoskar, A.V., Fegely, K. and Rajabi-Siahboomi, A.R.
Modulation of drug release from hypromellose (HPMC) matrices:
suppression of the initial burst effect.2006,
www.colorcon.com/pharma.
53. Chien-Chi Lin , Andrew T. Metters, Advanced Drug Delivery Reviews,
58, 2006; pp.1379–1408.
54. Higuchi T. Mechanism of sustained action medication, theoretical
analysis of rate of release of solid drugs dispersed in solid matrices. J
Pharm Sci 1963; 52. pp.1145-9
224
55. J.L. Ford, M.H. Rubinstein, F. McCaul, J.E. Hogan, P. Edgar,
Importance of drug type, tablet shape and added diluents on drug
release kinetics from Hydroxypropylmethylcellulose matrix tablets.
Int. J. Pharm., 1987;40, pp. 223-234.
56. L.C. Feely, S.S. Davis, The influence of polymeric excipients on drug
release from Hydroxypropylmethylcellulose matrices, Int. J.
Pharm.1988; 41, pp. 83–90.
57. J.E. Hogan, Hydroxypropylmethylcellulose sustained release
technology, Drug Dev. Ind. Pharm. 1998; 15, p. 975–999.
58. Higuchi T. Mechanism of sustained action medication, theoretical
analysis of rate of release of solid drugs dispersed in solid matrices. J
Pharm Sci 1963; 52. pp. 1145-9
59. Peppas. N.A, Sahlin. J.J. A simple equation for the description of
solute release: coupling of diffusion and relaxation. Int J Pharm 1989;
57: p. 169-72
60. Costa.P, Lobo.J.M.S. Modeling comparison of dissolution profiles. Eur
Jour Pharm Sci. 2001; 13: pp. 123
61. Mulye.N.V, Turco.S.T. An examination of assumptions underlying the
first-order kinetic model for release of water soluble drugs from
matrices. Drug Dev Ind Pharm 1996; 2 : pp. 673-9
62. Varelas. C.G, Dixon. D.G and Steiner. C. Zero-order release from
biphasic polymer hydrogels. Journal of Controlled Release, 1995; 34:
pp. 185-92
225
63. Christensen.F.N, Hansen.F.Y and Bechgaard.H. Physical
interpretation of parameters for drug release from controlled release
dosage forms. J Pharm Pharmacol 1980; 32: pp. 580
64. Hixon.A.W and Crowell.J.H. Dependence of reaction velocity upon
surface and agitation. Ind Eng Chem 1931; 23: p. 923-31
65. Korsmeyer.R.W, Gurny.R, Doelker.E, et al. Mechanisms of solute
release from porous hydrophilic polymers. Int J Pharm 1983; 15: pp.
25-35
66. Muller.F.B, Ha.H.R, Hotz.H et al. Once a day verapamil in essential
hypertension.Br Jour Clin Pharmacol. 1986; 21:143-7S.
67. Follath.F, Ha.H.R, Schutz.E et al. Pharmacokinetics of conventional
and slow release verapamil. Br Jour Clin Pharmacol. 1986; 21:pp. 149-
153.
68. Michael Weber, MD. Clinical safety and tolerability of losartan.Clinical
Therapeutics, 19, NO. 4, 1997 .pp. 604- 616
69. McIntyre.M, S. E. Gaffe, R. A. Michaluk and J. L. Reid. Losartan, an
orally active angiotensin (AT1) receptor antagonist: a review of its
efficacy and safety in essential hypertension. Pharmacol. Vol. 74, No.
2,1997; pp. 181-194.
70. Domenic.A. Sica, Todd W.B. Gehr and Siddhartha Ghosh. Clinical
Pharmacokinetics of Losartan. Clinical harmacokinets. 2005; 44 : pp.
797-814.
71. Bottenberg.P, Cleymaet. R, De Muynck.C, et al. Development and
testing of bioadhesive, fluoride-containing slow-release tablets for oral
use. J Pharm Pharmacol. 1991; 43: pp. 457–464.
226
72. K.E. Anderson, B.R. Stevenson, and J.A. Rogers, “Folic Acid-PEO
Labeled Liposomes To Improve Gastrointestinal Absorption of
Encapsulated Agents,” Journal of Controlled Release 1999 (2–3),
pp.189-198.
73. H. Suh et al., “Regulation of Smooth Muscle Cell Proliferation Using
Paclitaxel Loaded Poly(ethylene oxide)–Poly(lactide–glycolide)
Nanospheres,” J. Biomed. Mater. Res. 1998. pp. 331–338.
74. Yeh. M.K., Davis. S.S., and A.G. Coombes, “Improving Protein Delivery
from microparticles Using Blends of Poly(DL lactide co- glycolide) and
Poly(ethylene oxide)–Poly(propylene oxide) Copolymers,” Pharm. Res.
13; 1996; pp.1693–1698.
75. L. Liu et al., “Sandwiched Osmotic Tablet Core for Nifedipine
Controlled Delivery,” Biomed.Mater. Eng.1999; 9, pp. 297–310.
76. Jovanovic. M, Jovicic.G, Duvic.Z, et al. Effect of fillers and lubricants
on acetylsalicylic acid release kinetics from eudragit matrix tablets.
Drug Dev Ind Pharm. 1997; 23(6): pp. 595–602.
77. Gupta.V.K, Beckert .T.E and Price.J.C. A novel pH- and time-based
multi unit Potential colonic drug delivery system. I. Development. Int
Jour Pharm. 2001; 213: pp. 83–91.
78. Gupta.V.K, Assmus.M.W, Beckert.T.E and Price.J.C. A novel pH- and
time based multi unit potential colonic drug delivery system. II
Optimization of multiple response variables. Int Jour Pharm. 2001;
213: pp. 93–102.
79. Umejima H, Kim N-S, Ito T, et al. Preparation and evaluation of
Eudragit gels: in vivo evaluation of Eudispert rectal hydrogel and
227
xerogel containing salicylamide. Jour Pharm Sci 1993; 82: pp.195–
199.
80. Hartman.A.W, Nesbitt.R.U, Smith.F.M and Nuessle.N.O. Viscosities of
acacia and sodium alginate after sterilization by cobalt-60. J Pharm
Sci 1975; 64: pp.802–805.
81. Tonnesen.H.H and Karlsen.J. Alginate in drug delivery systems. Drug
Dev Ind Pharm. 2002; 28(6): pp.621–630.
82. Veski.P and Marvola. M. Sodium alginates as diluents in hard gelatin
capsules containing ibuprofen as a model drug. Pharmazie. 1993; 48
(10): pp.757–760.
83. Azarmi.S, Valizadeh.H, Barzegar.J.M and Loebenberg R. ’In situ’
crosslinking of polyanionic polymers to sustain the drug-release of
acetazolamide tablets. Pharm Ind. 2003; 63(9): pp.877–881.
84. Rajaonarivony.M, Vauthier.C, Couarraze.G, et al. Development of a
new drug carrier made from alginate. Jour Pharm Sci 1993; 82(9): pp.
912–917.
85. Attia MA, ElGibaly I, Slialtout SE. Transbuccal permeation, anti
inflammatory and clinical efficacy of piroxicam formulated in different
gels. Int J Pharm, 2004; 276: pp. 11– 28.
86. Balasubramaniam. J and Pandit. J.K. Ion-activated in situ gelling
systems for Sustained release ophthalmic delivery of ciprofloxacin
hydrochloride. Drug Delivery 2003; 10(3): pp. 185–191.
87. Kubo.W, Miyazaki.S and Attwood.D. Oral sustained delivery of
paracetamol from in situ gelling gellan and sodium alginate
formulations. Int Jour Pharm 2003; 258(1–2): pp. 55–64.
228
88. Narisawa S, Yoshino H, Hirakawa Y, Noda K. Porosity-controlled ethyl
cellulose film coating. IV. Evaluation of mechanical strength of porous
ethyl cellulose film. Chem Pharm Bull 1994; 42(7): pp. 1491–1495.
89. Sadeghi F, Ford JL, Rubinstein MH, Rajabi-Siahboomi AR. Study of
drug release from pellets coated with surelease containing HPMC. Drug
Dev Ind Pharm 2001; 27(5): pp. 419–430.
90. Pollock.D and Sheskey.P. Micronized ethylcellulose: opportunities in
direct compression controlled-release tablets. Pharm Technol. 1996;
20,9: pp.120–130.
91. FAO/WHO. Evaluation of certain food additives and contaminants.
Twenty-ninth report of the joint FAO/WHO expert committee on food
additives. World Health Organ Tech Rep Ser. 1986; No. 733.
92. Bumphrey.G. ‘Extremely useful’ new suspending agent. Pharm J.
1986; pp. 237: 665.
93. Evans.B.K and Fenton May.V.K. Xanthan gum: Pharmaceutical
excipient. Pharm J 1986; 237: pp. 736–737.
94. Chollet.J.K, Jozwiakowski. M.J, Phares.K.R, et al. Development of a
topically active imiquimod formulation. Pharm Dev Technol. 1999; 4:
pp.35–43.
95. Talukdar .M, Van der Mooter G, Augustijus P. In vivo evaluation of
xanthan gum as a potential excipient for oral controlled-release matrix
tablet formulation. Int J Pharm 1998; 169: p p.105–113.
96. Lu.M.F, Woodward.L and Borodkin.S. Xanthan gum and alginate
based controlled release theophylline formulations. Drug Dev Ind
Pharm 1991; 17: pp.1987–2004.
229
97. Dhopeshwarkar. V and Zatz. J.L. Evaluation of xanthan gum in the
preparation of sustained release matrix tablets. Drug Dev Ind Pharm
1993; 19: pp. 999–1017.
98. Billa.N, Yuen.K.H, Khader.M.A and Omar.A. Gamma scintigraphic
study of the gastrointestinal transit and in vivo dissolution of a
controlled release diclofenac sodium formulation in xanthan gum
matrices. Int J Pharm 2000; 201: pp. 109–120.
99. Peh. K.K & Wong. C.F. Application of similarity factor in the
development of controlled release diltiazem tablet. Drug Dev Ind
Pharm 2000; 26: pp.723–730.
100. Ceulemans.J, Vinckier.I and Ludwig.A. The use of xanthan gum in an
ophthalmic liquid dosage form: rheological characterization of the
interaction with mucin. J. Pharm. Sci 2002; 91(4): pp. 1117–1127.
101. Jenkins. D.J, Wolever TM, Hockaday TD, et al. Treatment of diabetes
with guar gum: reduction of urinary glucose loss in diabetics. Lancet,
1977; ii: pp. 779–780.
102. Khullar. R, Khar. R.K and Agarwal SP. Guar gum as a hydrophilic
matrix for preparation of theophylline controlled-release dosage
form. Indian J. Pharm. Sci 1999; 61(6): pp. 342–345.
103. Feinstein. W and Bartilucci. A.J. Comparative study of selected
Disintegrating agents. J. Pharm. Sci. 1966; 55: pp. 332–334.
104. Sakr.A.M, Elsabbagh.H.M. Evaluation of guar gum as a tablet
additive: A preliminary report. Pharm Ind 1977; 39(4): pp. 399–403.
105. Adkin. D.A, Kenyon. C.J, Lerner. E.I, et al. The use of scintigraphy to
provide ‘‘proof of concept’’ for novel polysaccharide preparations
230
designed for colonic drug delivery. Pharm Res 1997; 14(1): pp.103–
107.
106. Wong. D, Larrabee. S, Clifford. K, et al. USP Dissolution Apparatus II
(reciprocating cylinder) for screening of guar based colonic delivery
formulations. Journal of Controlled Release, 1997; 47: pp.173–179.
107. Al-Saiden. S.M, Krishnaiah. Y.S, Satyanorayana. V, et al.
Pharmacokinetic evaluation of guar gum-based three-layer matrix
tablets for oral controlled delivery of highly soluble metoprolol
tartrate as a model drug. Eur J Pharm Biopharm 2004; 58(3): pp.
697– 703.
108. Verbeken.D, Dierckx.S and Dewettinck.K. Exudate gums:
occurrence, production, and applications. Appl Microbiol
Biotechnol . 2003; 63: pp.10-21.
109. Munday. D.L and Cox. P.J. Compressed xanthan and karaya gum
matrices: Hydration, erosion and drug release mechanisms. Int J
Pharm. 2000; 203: pp.179–92.
110. Park.C.R and Munday. D.L. Evaluation of selected polysaccharide
excipients in buccoadhesive tablets for sustained release of nicotine.
Drug Develop Ind Pharm. 2004; 30: pp.609–17.
111. Ceballos. A, Cirri. M, F. Maestrelli , G. Corti and P. Mura. Influence of
formulation and process variables on in vitro release of theophylline
from directly-compressed Eudragit matrix tablets IL Farmaco. 2005 ;
60, pp.913–918.
112. Ning Wua, Li-Shan.W, Darren Cherng Wen. T, Shabbir M.
Moochhalab and Y i-Yan Yanga. Mathematical modeling and in vitro
231
study of controlled drug release via a highly swellable and dissoluble
polymer matrix: polyethylene oxide with high molecular weights.
Journal of Controlled Release, 2005; 102, pp.569– 581
113. Shahla Jamzad and Reza Fassihi. Development of a controlled release
low dose class II drug-Glipizide. Int Journal of Pharmaceutics. 2006;
312, pp.24–32
114. Atul.K, Ashok. K. Tiwary, Narendra.K.Jain and Subheet Jain.
Formulation and In Vitro, In Vivo Evaluation of Extended- release
Matrix Tablet of Zidovudine: Influence of Combination of Hydrophilic
and Hydrophobic Matrix Formers AAPS Pharm Sci Tech, 2006; 7 (1),
E1-9
115. Per Borgquist , Anna. K , Lennart.P , Anette.L and Anders.A. A model
for the drug release from a polymer Matrix tablet effects of swelling and
dissolution. Journal of Controlled Release 113. 2006, pp. 216–225.
116. Celine.V. L, Lai Wah.C, Ching.A.L. and Sia Heng P. W. Evaluation of
sodium alginate as drug release modifier in matrix tablets. Int J
Pharm. 2006; pp. 25–37
117. Varshosaz.J, Naser .T and Fatemeh K. Use of hydrophilic natural
gums in formulation of sustained-release matrix tablets of tramadol
hydrochloride. AAPS PharmSciTech. 2006; 7 (1). Pp.1-6.
118. Sandra. F, Marzia. C, Francesca.M, Giovanna.C and Paola.M. Study of
formulation variables influencing the drug release rate from matrix
tablets by experimental design. European Jour. of Pharma. and
Biopharm. 2006; 62, pp. 77– 84.
232
119. Thawatchai. P and Garnpimol C. R. Formulation Variables
Influencing Drug Release from Layered Matrix System comprising
chitosan and xanthan gum. AAPS PharmSciTech. 2008; pp.870-877.
120. Hongtao. Li, Robert. J. H and Xiaochen. Gu. Effect of Drug
Solubility on Polymer Hydration and Drug Dissolution from Poly
(ethylene Oxide) Matrix Tablets. AAPS PharmSciTech, 2008;Vol. 9,
121. Praveen S. H and Ranendra N. S. Oral matrix tablet formulations for
concomitant controlled release of anti-tubercular drugs: design and in
vitro evaluations. International Journal of Pharmaceutics.2008; 362,
pp.118–125.
122. Rouslan.I.M , Evgeniya.B.M , Liliya F. S, Vera A. K & Guy Van den
Mooter. Comparative evaluation of interpolyelectrolyte complexes of
chitosan with Eudragit_ L100 and Eudragit_ L100-55 as potential
carriers for oral controlled drug delivery European Jour.of
Pharmaceutics and Biopharm.70 ,2008; pp.215–225.
123. Baojian. Wu, Daoyin. D, Yi Lu, Wei Wu. Biphasic release of
indomethacin from HPMC/pectin/calcium matrix tablet: II.
Influencing variables, stability and pharmacokinetics in dogs.
European Jour. of Pharmaceutics and Biopharm. 69 , 2008; pp.294–
302.
124. Sung.I.H and Seaung.Y.O. Dissolution kinetics and physical
characterization of three-layered tablet with poly(ethylene oxide) core
matrix capped by Carbopol. Int J Pharm.2008; 356, pp.121–129.
125. Hamdy. A, Ossama. Y. A and Hesham Salem. Formulation of
Controlled-Release Baclofen Matrix Tablets II: Influence of Some
233
Hydrophobic Excipients on the Release Rate and In Vitro Evaluation
AAPS Pharm Sci Tech,2007;9, No. 2, .pp. 156 – 166.
126. Jolly.M.Sankalia , Mayur.G.Sankalia and Rajashree.C. Mashru. Drug
release and swelling kinetics of directly compressed glipizide
sustained-release matrices: Establishment of level A IVIVC. Journal of
Controlled Release. 129, 2008, pp.49–58.
127. Dorottya. K , Károly. S and Romána Z. The effect of storage and active
ingredient properties on the drug release profile of poly(ethylene oxide)
matrix tablets. Carbohydrate Polymers.2008; 74, pp.930–933.
128. Anna .K, Anette. L, Andersson. ASA and Lennart P. Swelling and
Polymer Erosion for Poly(Ethylene Oxide) Tablets of Different
Molecular Weights Polydispersities. Journal of Pharmaceuticalical
sciences. 2009, 10.1002/.21892
129. Jelena. P, Jelena .J, Svetlana. I and Zorica Ð. Modelling of diclofenac
sodium diffusion from swellable and water- soluble polyethylene oxide
matrices Journal of Pharmacy and Pharmacology 2009; 61: pp.1449–
1456
130. Kanika.G, Nikhil. K and Anil. P. Formulation and evaluation of once-
daily sustained Release venlafaxine hydrochloride tablet using
Hydrophilic matrix. Journal of Pharmacy Research. 2009, 2(8),
pp.1287-1291.
131. Khemariya.P, Jain A.K, Bhargava.M, Singhai.S.K, Goswami. S and
Goswami. R. Preparation and in-vitro evaluation of sustained- release
matrix tablets of diltiazem. Int Journal of Advances in pharmaceutical
Sciences. 2010; pp.267-273.
234
132. Faith Chaibva , Michael Burton and Roderick B. Walker. Optimization
of salbutamol sulfate dissolution from sustained release matrix
formulations using an artificial neural network . Pharmaceutics, 2010,
2, pp.182–198.
133. Manish.G , Lee.A.H, Janet.B, Bridget.O.M, Fiona.J.M, Alexander.B.M
, Howard. N.E.S. In vitro and in vivo erosion profiles of
hydroxypropylmethylcellulose matrix tablets. Journal of Controlled
Release.2010: 147, pp.70–75.
134. Tomokazu.T, Shigeaki.M, Ryosaku.S, Masazumi.S, Shigeyuki Y,
Yukihiro O, Satoshi K. Release mechanisms of acetaminophen from
polyethyleneoxide/polyethylene glycol matrix tablets utilizing magnetic
resonance imaging International Journal of Pharmaceutics 395; 2010,
pp.147–153
135. Martti.M , Anneli.K , Heikki.A and Sirkka.N. The effect of food on
gastrointestinal transit and drug Absorption of a multiparticular
sustained-release verapamil. International Journal of Pharmaceutics.
1989; 53, pp.145-155.
136. Seham.A.E. Interaction of Verapamil hydrochloride with carbopol
934p and its effect on the release rate of the drug and the water
uptake of the polymer matrix. Drug Development and Industrial
Pharmacy, Vol 27, 2001; pp.925– 934.
137. Thomas. D and Reza F. Guar-based monolithic matrix systems: Effect
of ionizable and non-ionizable substances and excipients on gel
dynamics and release kinetics. Journal of controlled release. 80, 2002;
pp. 45–56.
235
138. Nadia.P, Beatrice.P, Beatrice.A, Dario.V, Mariarosa.M and
Lorenzo.R.C. Controlled release of verapamil hydrochloride from
waxy microparticles prepared by spray congealing Journal of
Controlled Release.2003; 88, pp. 263–275.
139. Munish.D, Poddar.S.S and Shajahan.A. Development of matrix and
coated units for pH independent release of weakly basic drug.
Pharmacy On line. 2003.
140. Mukesh.C.G, Tejas.P.P, and Shital.H.B. Studies in Preparation and
Evaluation of pH-Independent sustained-release matrix tablets of
verapamil Hcl using directly compressible eudragits. Pharmaceutical
Development and Technology.2003 Vol. 8, No.4, pp.323–333.
141. Aditya.S.T, Ketan.A.Mehta, Larry.A, Stephen.W.Hoag. Influence of
methacrylic and acrylic acid polymers on the release performance of
weakly basic drugs from sustained release hydrophilic matrices.
Journal of pharmaceutical sciences, 2004:Vol. 93, No. 9. pp.2319-
2331.
142. Omaima.N. El-Gazayerly, Vipaporn.R, and James W. Ayres. Novel
chewable sustained-release tablet containing verapamil hydrochloride.
Pharmaceutical Development and Technology. Vol. 9, No. 2, 2004;
pp.181–188.
143. Evren A, Muge. K, Ayşegul K, Nilufer Y and Tamer B. J. Fac. Pharm,
Ankara. 2004;33. pp. 125 - 137 .
144. Mohammad Reza Siahi, Mohammad Barzegar-Jalali, Farnaz
Monajjemzadeh, Fatemeh Ghaffari and Shirzad Azarmi. Design and
Evaluation of 1- and 3-Layer Matrices of Verapamil Hydrochloride for
236
Sustaining Its Release. AAPS PharmSciTech; 6 (4). 2005; pp. 626-
632.
145. George P & Nikolaos B. Swelling studies and in vitro release of
verapamil from calcium alginate and calcium alginate–chitosan
beads International Journal of Pharmaceutics.323. 2006. 34–42.
146. Sandile M. K and Roderick B. W. Evaluation of rate of swelling and
erosion of verapamil sustained release matrix tablets. Drug
Development and Industrial Pharmacy, 32:2006; pp.1139–1148.
147. Sasidhar. R.L.C, Vidyadhara. S and Srinivasa Babu. P. Development
of verapamil hydrochloride controlled release tablets using poly
(ethyleneoxides). The Indian Pharmacist. vol. 6, 2007; pp.96-98.
148. Tamara.G¸ Alves.A, Ali.R, Rajabi.S, Isidoro C. Application of
percolation theory in the study of an extended release Verapamil
hydrochloride formulation. International Journal of Pharmaceutics
361- 2008. pp.112– 117.
149. Durgacharan.A.B, Pravin.S.K and Dinesh.M.S. Sustained release
matrices of verapamil HCl using glyceryl monosterate and stearic acid
Research Jour. Pharm. and Tech. 2008: 1(4): pp.405-409.
150. Bistra.K, Elena.K and Ivo Ivanov, George. M and George.G.
Verapamil hydrochloride release characteristics from new copolymer
zwitterionic matrix tablets Pharmaceutical Development and
Technology, 2008,13: pp.311–321.
151. Gutsche.S. Strategies to overcome pH-dependent solubility of weakly
basic drugs by using different types of alginates. Drug Development
and Industrial Pharmacy, 2008: 34: pp.1277–1284.
237
152. Vishnu.M.Patel, Bhupendra.G.P and Anand.K.Patel. Controlled release
gastroretentive dosage form of verapamil hydrochloride International
Journal of PharmTech Research. 2009, Vol.1, No.2, pp 215- 221.
153. Durgacharan. A.B, Pravin. S. K and Dinesh M. Formulation and in
vitro evaluation of sustained release verapamil hydrochloride using
recirol ATO5 through melt granulation technique. Asian journal of
Pharmaceutics, 2009. pp. 278-285.
154. Kumud Kumar Padhy1, Kalpana Swain and K. A. Chowdary.
Influence of organic acids on drug release pattern of verapamil
hydrochloride pellets. Journal of Advanced Pharmaceutical
Research. 2010, 1, pp. 65-73.
155. Farhana SA, Shantakumar. S.M, Shyale. S, Shalam .M and Narasu L.
Sustained release of verapamil hydrochloride from sodium lginate
microcapsules. Current Drug Delivery. 2010Apr; 7 (2): pp.98- 108.
156. Shruti.C, Gayathri.V. P and Sanjay K. M. Release modulating
hydrophilic matrix systems of losartan potassium: Optimization of
formulation using statistical experimental design. European Journal of
Pharmaceutics and Biopharmaceutics.2007; 66, pp.73–82.
157. Sasidhar.R.L.C, Vidyadhara.S, Ramesh Babu.J, Nagaraju.R and
Prakash Reddy.K. Formulation and evaluation of controlled release of
losartan potassium matrix tablets using poly (ethylene oxides). Current
Trends in Biotechnology and Pharmacy.2009; Vol. 3, pp.320 – 328.
158. Prasant kumar.R and Bhabani Shankar.N. Formulation design,
preparation of losartan potassium microspheres by solvent
238
evaporation method and its in vitro characterization. Arch Pharm Sci
& Res. 2009; Vol 1, pp.166 –170.
159. Prajapati B.G. and Patel K.R. Once-daily sustained-release matrix
tablets of losartan potassium: Formulation and in vitro evaluation
International Journal of Medical and Clinical Research. 2009; Vol. 1,
Issue 1, pp.01-07.
160. Raju.D.B, Suresh John.K and Varma.M.M . Formulation and
evaluation of losartan potassium matrix tablets for oral controlled
release J. Chem. Pharm. Res., 2010, 2: pp.130-135.
161. Ravi sankar.V, Dastagiri Reddy.Y, Nageswara Rao.A and
Dhachinamoorthy.D and Chandra sekhar. K.B. Effect of
Hydrophylicand Hydrophobic Polymers on Losartan Potassium matrix
tablet. Journal of Pharmacy Research. 2010, 3(9), pp. 2195-2197.
162. Pavithra .T.K, Harshitha .R, Panneer .K, Renuka .S, Prakash Rao .B
and Narendra .C. Formulation and Evaluation of Hydrogel Based
Oral Controlled Drug Delivery System for Antihypertensive
Drug.Journal of Pharmaceutical Science and Technology.2010.Vol.2
(8), pp. 276-283.
163. Bistra K. and Dimitar R. New co-polymer zwitterionic matrices for
sustained release of verapamil hydrochloride. Acta Pharm. 2007, 57
;429–439
164. Indian Pharmacopoeia, Vol. II., 2007, p.1319.
165. United States Pharmacopoeia, 30th edn., Vol II., p.2499.
166. Yalcın Ozkan , Niyazi Yılmaz , Sibel A. O and Inci B. High-performance
liquid chromatographic analysis of verapamil and its application to
239
determination in tablet dosage forms and to drug dissolution studies.
Il Farmaco. 2000, 55; pp.376–382
167. Deanne.L. Hertzog.A, Jennifer Finnegan McCafferty B, Xueguang
Fang b, Jeffrey Tyrrell c, Robert A. Reed. Development and validation
of a stability indicating HPLC method for the simultaneous
determination of Losartan potassium, hydrochlorothiazide, and their
degradation products. Journal of Pharma. and Biomedical Analysis.
2002; 30, pp.747–760
168. Quality control. 4 th ed. Pharmaceutical statistics: Practical and
clinical applications. In: Bolton S, Bon C, editors. New York: Marcel
Dekker: 2004. p.408-411.
169. Moore.J.W. and Flanner.H.H. Mathematical comparison of dissolution
profiles. Pharm. Tech. 1996 20, pp.64–74.
170. ICH, QIA Stability testing of new dosage forms. International
conference on Harmonization, Geneva, October. 1993.
171. Peck.G.E, Baley.G.J, McCurdy.V.E and Banker.G.S. Tablet
formulation and design. Pharmaceutical Dosage Forms, Tablets 2nd
Ed, Marcel Dekker, New York 1989; 109-112.
172. Raymond C Rowe, Paul .J. S, Sian C. O. Handbook of Pharmaceutical
Excipients, Pharmaceutical Press, Fifth edition, 2006; Pp 656-658.